Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

140.06 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy ↗

October 13, 2025

FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the therapy's overall benefit.

Via Benzinga

Wall Street Suffers Worst Day Since April as Trump Revives Trade War Fears ↗

October 13, 2025

U.S. markets were rattled on Friday after President Trump reignited trade tensions with China, triggering the sharpest sell-off since April. Tech and AI stocks led the decline, while gold and...

Via Chartmill

Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today ↗

October 10, 2025

The company could soon be swallowed by a very large peer -- which also happens to be a business partner.

Via The Motley Fool

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

October 10, 2025

Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

9 Analysts Assess Protagonist Therapeutics: What You Need To Know ↗

June 03, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 10, 2025

Via Benzinga

Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report ↗

October 10, 2025

Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug portfolio.

Via Benzinga

Which stocks are experiencing notable movement on Friday? ↗

October 10, 2025

Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

5 Analysts Assess Protagonist Therapeutics: What You Need To Know ↗

October 08, 2025

Via Benzinga

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill

October 07, 2025

Via ACCESS Newswire

Demystifying Protagonist Therapeutics: Insights From 4 Analyst Reviews ↗

September 17, 2025

Via Benzinga

Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials ↗

September 17, 2025

Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis.

Via Benzinga

This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

September 17, 2025

Via Benzinga

Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress

September 17, 2025

Via ACCESS Newswire

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025

September 15, 2025

Via ACCESS Newswire

This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗

September 12, 2025

Via Benzinga

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency

September 11, 2025

Via ACCESS Newswire

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025

August 26, 2025

Via ACCESS Newswire

Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera

August 25, 2025

Via ACCESS Newswire

What 4 Analyst Ratings Have To Say About Protagonist Therapeutics ↗

August 07, 2025

Via Benzinga

Protagonist (PTGX) Q2 Revenue Falls 26% ↗

August 07, 2025

Via The Motley Fool

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 06, 2025

Via ACCESS Newswire

Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis

July 21, 2025

Via ACCESS Newswire

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? ↗

June 30, 2025

The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.

Via Investor's Business Daily

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity

June 30, 2025

Via ACCESS Newswire

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

June 26, 2025

Via ACCESS Newswire

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

June 01, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

May 21, 2025

Via ACCESS Newswire

PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) showing some interesting technicals. Here's why. ↗

May 15, 2025

Interesting Technical Analysis finding for PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX): Indications Suggest NASDAQ:PTGX Could Be on the Verge of a Breakout.

Via Chartmill

Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study ↗

May 09, 2025

Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.